NUNZIA PHARMACEUTICAL Co

2022 Q4 Form 10-Q Financial Statement

#000168316822007586 Filed on November 14, 2022

View on sec.gov

Income Statement

Concept 2022 Q4 2022 Q3 2021 Q3

Balance Sheet

Concept 2022 Q4 2022 Q3 2021 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $35.37K $480.00
YoY Change 7268.75%
Cash & Equivalents $30.37K $484.00
Short-Term Investments $5.000K
Other Short-Term Assets $4.000K
YoY Change
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $35.37K $4.480K
YoY Change 689.51%
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments $5.000K
YoY Change
Other Assets
YoY Change
Total Long-Term Assets $3.00 $5.000K
YoY Change -99.94%
TOTAL ASSETS
Total Short-Term Assets $35.37K $4.480K
Total Long-Term Assets $3.00 $5.000K
Total Assets $35.37K $9.480K
YoY Change 273.13%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $43.35K $11.24K
YoY Change 285.68% -54.6%
Accrued Expenses
YoY Change
Deferred Revenue
YoY Change
Short-Term Debt $183.4K $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $226.7K $97.69K
YoY Change 132.05% 176.74%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $23.00K
YoY Change -100.0%
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities $0.00 $23.00K
YoY Change -100.0%
TOTAL LIABILITIES
Total Short-Term Liabilities $226.7K $97.69K
Total Long-Term Liabilities $0.00 $23.00K
Total Liabilities $226.7K $120.7K
YoY Change 87.83% 241.9%
SHAREHOLDERS EQUITY
Retained Earnings -$198.4M
YoY Change
Common Stock
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$191.3K -$111.2K
YoY Change
Total Liabilities & Shareholders Equity $35.37K $9.480K
YoY Change 273.13%

Cashflow Statement

Concept 2022 Q4 2022 Q3 2021 Q3

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2021Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
usd
CY2021Q2 NUNZ Merger Shares Issued Value
MergerSharesIssuedValue
usd
dei Entity Central Index Key
EntityCentralIndexKey
0000886093
dei Amendment Flag
AmendmentFlag
false
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2022
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2022Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
usd
CY2021Q2 NUNZ Return Of Merger Shares Issued In Error Value
ReturnOfMergerSharesIssuedInErrorValue
usd
CY2021Q3 NUNZ Common Stock Issued For License Agreement With Michael Mitsunaga
CommonStockIssuedForLicenseAgreementWithMichaelMitsunaga
usd
CY2021Q3 NUNZ Shares Issued Under Mutual Sales And Marketing Agreement
SharesIssuedUnderMutualSalesAndMarketingAgreement
usd
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2022-09-30
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
000-22744
dei Entity Registrant Name
EntityRegistrantName
NUNZIA PHARMACEUTICAL COMPANY
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
UT
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
87-0442090
dei Entity Address Address Line1
EntityAddressAddressLine1
1627 West 14th Street
dei Entity Address City Or Town
EntityAddressCityOrTown
Long Beach
dei Entity Address State Or Province
EntityAddressStateOrProvince
CA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
90813
dei City Area Code
CityAreaCode
(714)
dei Local Phone Number
LocalPhoneNumber
609-9117
dei Entity Current Reporting Status
EntityCurrentReportingStatus
No
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
No
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2022Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
434514578 shares
CY2022Q3 us-gaap Cash
Cash
30373 usd
CY2021Q4 us-gaap Cash
Cash
131 usd
CY2022Q3 us-gaap Investment Owned At Cost
InvestmentOwnedAtCost
5000 usd
CY2021Q4 us-gaap Investment Owned At Cost
InvestmentOwnedAtCost
5000 usd
CY2022Q3 us-gaap Assets
Assets
35373 usd
CY2021Q4 us-gaap Assets
Assets
5131 usd
CY2022Q3 us-gaap Accounts Payable And Other Accrued Liabilities Current
AccountsPayableAndOtherAccruedLiabilitiesCurrent
43349 usd
CY2021Q4 us-gaap Accounts Payable And Other Accrued Liabilities Current
AccountsPayableAndOtherAccruedLiabilitiesCurrent
1862 usd
CY2022Q3 NUNZ Related Party Shareholder Note Payable
RelatedPartyShareholderNotePayable
40500 usd
CY2021Q4 NUNZ Related Party Shareholder Note Payable
RelatedPartyShareholderNotePayable
0 usd
CY2022Q3 us-gaap Notes Payable Related Parties Classified Current
NotesPayableRelatedPartiesClassifiedCurrent
142845 usd
CY2021Q4 us-gaap Notes Payable Related Parties Classified Current
NotesPayableRelatedPartiesClassifiedCurrent
97443 usd
CY2022Q3 us-gaap Liabilities Current
LiabilitiesCurrent
226694 usd
CY2021Q4 us-gaap Liabilities Current
LiabilitiesCurrent
99305 usd
CY2022Q3 us-gaap Liabilities
Liabilities
226694 usd
CY2021Q4 us-gaap Liabilities
Liabilities
99305 usd
CY2022Q3 NUNZ Common Stock Payable
CommonStockPayable
31650 usd
CY2021Q4 NUNZ Common Stock Payable
CommonStockPayable
31650 usd
CY2022Q3 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
197735239 usd
CY2021Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
178853134 usd
CY2022Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-198392776 usd
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-179413129 usd
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
-191321 usd
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
-94174 usd
CY2022Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
35373 usd
CY2021Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
5131 usd
CY2022Q3 us-gaap Revenues
Revenues
0 usd
CY2021Q3 us-gaap Revenues
Revenues
0 usd
us-gaap Revenues
Revenues
0 usd
us-gaap Revenues
Revenues
0 usd
CY2022Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
211416 usd
CY2021Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
34526 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
249902 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
56803 usd
CY2022Q3 us-gaap Other Selling General And Administrative Expense
OtherSellingGeneralAndAdministrativeExpense
16013 usd
CY2021Q3 us-gaap Other Selling General And Administrative Expense
OtherSellingGeneralAndAdministrativeExpense
0 usd
us-gaap Other Selling General And Administrative Expense
OtherSellingGeneralAndAdministrativeExpense
18720757 usd
us-gaap Other Selling General And Administrative Expense
OtherSellingGeneralAndAdministrativeExpense
0 usd
CY2022Q3 us-gaap Operating Expenses
OperatingExpenses
227429 usd
CY2021Q3 us-gaap Operating Expenses
OperatingExpenses
34526 usd
us-gaap Operating Expenses
OperatingExpenses
18970659 usd
us-gaap Operating Expenses
OperatingExpenses
56803 usd
CY2022Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-227429 usd
CY2021Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-34526 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-18970659 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-56803 usd
CY2022Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-8987 usd
CY2021Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
0 usd
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-8987 usd
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
0 usd
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-236416 usd
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
-34526 usd
us-gaap Net Income Loss
NetIncomeLoss
-18979647 usd
us-gaap Net Income Loss
NetIncomeLoss
-56803 usd
CY2022Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.00
CY2022Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.00
CY2021Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.00
CY2021Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.00
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.04
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.04
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.00
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.00
CY2022Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
434436861 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
434237270 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
434237270 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
290892866 shares
CY2022Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
434436861 shares
CY2021Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
292769578 shares
CY2021Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
292769578 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
290892866 shares
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
-63204 usd
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-15648 usd
CY2021Q1 us-gaap Stockholders Equity
StockholdersEquity
-78852 usd
CY2021Q2 NUNZ Shares Issued Under Sales And Marketing Agreement
SharesIssuedUnderSalesAndMarketingAgreement
5000 usd
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
-6629 usd
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
-80481 usd
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
-34526 usd
CY2021Q3 us-gaap Stockholders Equity
StockholdersEquity
-115007 usd
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
-94174 usd
CY2022Q1 us-gaap Adjustments To Additional Paid In Capital Convertible Debt With Conversion Feature
AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature
18685000 usd
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-18723130 usd
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
-132304 usd
CY2022Q2 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
34930 usd
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-20100 usd
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
-117405 usd
CY2022Q3 us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
62500 usd
CY2022Q3 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
100000 usd
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-236416 usd
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
-191321 usd
us-gaap Net Income Loss
NetIncomeLoss
-18979647 usd
us-gaap Net Income Loss
NetIncomeLoss
-56803 usd
us-gaap Share Based Compensation
ShareBasedCompensation
18747500 usd
us-gaap Share Based Compensation
ShareBasedCompensation
0 usd
us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
-0 usd
us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
4000 usd
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
41486 usd
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-14629 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-190660 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-75432 usd
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
135000 usd
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
0 usd
us-gaap Proceeds From Related Party Debt
ProceedsFromRelatedPartyDebt
85902 usd
us-gaap Proceeds From Related Party Debt
ProceedsFromRelatedPartyDebt
75916 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
220902 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
75916 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
30242 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
484 usd
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
131 usd
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
0 usd
us-gaap Interest Paid Net
InterestPaidNet
0 usd
CY2022Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
30373 usd
CY2021Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
484 usd
us-gaap Interest Paid Net
InterestPaidNet
0 usd
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
0 usd
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
0 usd
CY2022Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-198392776 usd
CY2022Q3 NUNZ Working Capital
WorkingCapital
-191322 usd
us-gaap Use Of Estimates
UseOfEstimates
<p id="xdx_848_eus-gaap--UseOfEstimates_znNWVK7KmwZ4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i><span style="text-decoration: underline"><span id="xdx_864_zncuOYTnoev7">Accounting estimates</span></span></i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The preparation of financial statements in conformity with U.S. generally accepted accounting principles (“GAAP”) requires Management to make estimates and assumptions that affect the reported amounts of stock-based compensation, assets and liabilities, and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ significantly from those estimates.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p>
CY2022Q3 us-gaap Cash
Cash
30373 usd
CY2021Q4 us-gaap Cash
Cash
131 usd
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
0 shares
CY2021 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
0 shares
CY2022Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
1.00
CY2022Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
50000000 shares
CY2022Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2021Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
270000 shares
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
135000 usd
us-gaap Stock Issued During Period Shares Issued For Services
StockIssuedDuringPeriodSharesIssuedForServices
125000 shares
us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
62500 usd

Files In Submission

Name View Source Status
FilingSummary.xml Edgar Link unprocessable
0001683168-22-007586-index-headers.html Edgar Link pending
0001683168-22-007586-index.html Edgar Link pending
0001683168-22-007586.txt Edgar Link pending
0001683168-22-007586-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
nunz-20220930.xsd Edgar Link pending
nunzia_ex3101.htm Edgar Link pending
nunzia_ex3102.htm Edgar Link pending
nunzia_ex3201.htm Edgar Link pending
nunzia_i10q-093022.htm Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R2.htm Edgar Link pending
R3.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
nunz-20220930_def.xml Edgar Link unprocessable
nunz-20220930_pre.xml Edgar Link unprocessable
nunz-20220930_cal.xml Edgar Link unprocessable
nunz-20220930_lab.xml Edgar Link unprocessable
nunzia_i10q-093022_htm.xml Edgar Link completed